|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/14/22 MediXall Group, Inc. 10-Q 9/30/22 47:2.8M Edgar Filing LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 628K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 17K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 17K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 14K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 14K
11: R1 Cover HTML 64K
12: R2 Condensed Consolidated Balance Sheets (Unaudited) HTML 103K
13: R3 Condensed Consolidated Balance Sheets (Unaudited) HTML 38K
(Parenthetical)
14: R4 Condensed Consolidated Statements of Operations HTML 88K
(Unaudited)
15: R5 Consolidated Statements of Changes in HTML 80K
Stockholders' Equity (Deficit) (Unaudited)
16: R6 Consolidated Statements of Changes in HTML 17K
Stockholders' Equity (Deficit) (Unaudited)
(Parenthetical)
17: R7 Condensed Consolidated Statements of Cash Flows HTML 88K
(Unaudited)
18: R8 Organization and Nature of Operation HTML 20K
19: R9 Asset Acquisition HTML 19K
20: R10 Going Concern HTML 21K
21: R11 Summary of Significant Accounting Policies HTML 69K
22: R12 Right-to-use Intellectual Property HTML 30K
23: R13 Preferred Stock HTML 26K
24: R14 Related Party Transactions HTML 34K
25: R15 Senior Convertible Debentures and Warrants HTML 31K
26: R16 Summary of Significant Accounting Policies HTML 102K
(Policies)
27: R17 Summary of Significant Accounting Policies HTML 49K
(Tables)
28: R18 Right-to-use Intellectual Property (Tables) HTML 30K
29: R19 Related Party Transactions (Tables) HTML 26K
30: R20 Senior Convertible Debentures and Warrants HTML 25K
(Tables)
31: R21 Asset Acquisition (Details Narrative) HTML 22K
32: R22 Going Concern (Details Narrative) HTML 23K
33: R23 Summary of Significant Accounting Policies HTML 28K
(Schedule of Basic and Diluted EPS) (Details)
34: R24 Summary of Significant Accounting Policies HTML 22K
(Schedule of potentially dilutive securities)
(Details)
35: R25 Summary of Significant Accounting Policies HTML 18K
(Details Narrative)
36: R26 Right-to-use Intellectual Property (Schedule of HTML 22K
Right-to-use Intellectual Property) (Details)
37: R27 Right-to-use Intellectual Property (Schedule of HTML 30K
amortization expense for right-to-use intellectual
property) (Details)
38: R28 Preferred Stock (Details Narrative) HTML 37K
39: R29 Related Party Transactions (Details) HTML 32K
40: R30 Related Party Transactions (Details Narrative) HTML 29K
41: R31 Senior Convertible Debentures and Warrants HTML 30K
(Details)
42: R32 Senior Convertible Debentures and Warrants HTML 43K
(Details Narrative)
45: XML IDEA XML File -- Filing Summary XML 78K
43: XML XBRL Instance -- mdxl_10q_htm XML 646K
44: EXCEL IDEA Workbook of Financial Reports XLSX 71K
7: EX-101.CAL XBRL Calculations -- mdxl-20220930_cal XML 107K
8: EX-101.DEF XBRL Definitions -- mdxl-20220930_def XML 226K
9: EX-101.LAB XBRL Labels -- mdxl-20220930_lab XML 485K
10: EX-101.PRE XBRL Presentations -- mdxl-20220930_pre XML 398K
6: EX-101.SCH XBRL Schema -- mdxl-20220930 XSD 87K
46: JSON XBRL Instance as JSON Data -- MetaLinks 204± 287K
47: ZIP XBRL Zipped Folder -- 0001553350-22-000902-xbrl Zip 130K
Exhibit 32.1
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report of MediXall Group, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Travis Jackson, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Dated: November 14, 2022 | /s/ Travis Jackson |
| Travis Jackson | |
| Chief Executive Officer | |
| (principal executive officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/14/22 | None on these Dates | ||
| For Period end: | 9/30/22 | |||
| List all Filings | ||||